|
|
|
|
Gene Activity Variations Predict Lymphoma Survival
Patterns of gene activity in a type of non-Hodgkin lymphoma has given researchers a better understanding of factors that contribute to the survival of patients treated for the disease.Gene activity, or expression, is a measure of...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
- Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
-- Cytokinetics, Incorporated (NasdaqGM:CYTK - News) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of...
|
|
|
Stromal Gene Signatures in Large-B-Cell Lymphomas
_ Stromal Gene Signatures in Large-B-Cell Lymphomas.
|
|
|
US FDA grants priority review status for Cell Therapeutics' Zevalin
Cell Therapeutics, Inc (CTI) announced that the US Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin (...
|
|
|
FDA Grants Priority Review on Ibritumomab Tiuxetan Application
FDA Grants Priority Review on Ibritumomab Tiuxetan Application SEATTLE, Dec.1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted...
|
|
|
IRVINE--- Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed On
Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI) and Cell Therapeutics, Inc. (NASDAQ:CTIC)(MTA: CTIC) announced today they have entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, to commercialize and develop...
|
|
|
Variations In Gene Activity Can Predict The Survival Of Patients With Lymphoma
BETHESDA, Md., Nov.28, 2008-Patterns of gene activity in a type of non-Hodgkin lymphoma has given researchers a better understanding of factors that contribute to the survival of patients treated for the disease. Gene activity, or...
|
|
|
Bradmer Issued Patent in Europe for Use of Neuradiab to Treat Lymphoma
/PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it has been granted European Patent, # 1351713, entitled 'Anti...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
www.allos.com/ - Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration ...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc.(Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
rapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration ...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
(BUSINESS WIRE) -- Allos Therapeutics, Inc.(ALTH: ALTH News, chart, profile, more Last: Delayed quote data Add to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: , , ) , a biopharmaceutical company focused on the...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of Hematology (ASH)...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
(MARKET WIRE via COMTEX) -- GSK | Quote | Chart | News | PowerRating -- Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) announced today that an abstract summarizing interim clinical trial data evaluating SB...
|
|
|
Cytokinetics, Inc.: Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008
- Cytokinetics, Incorporated (NASDAQ Poster Presentation at ASH The following abstract is scheduled to be presented at ASH as follows: Abstract #1563: 'A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Administered...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
- Cytokinetics, Incorporated (NASDAQ Poster Presentation at ASH The following abstract is scheduled to be presented at ASH as follows: Abstract #1563: 'A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Administered...
|
|
|
Variations in Gene Activity Can Predict the Survival of Patients with Lymphoma
Patterns of gene activity in a type of non-Hodgkin lymphoma has given researchers a better understanding of factors that contribute to the survival of patients treated for the disease.Gene activity, or expression, is a measure of...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with
Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration ...
|
|
|
Variations in Gene Activity Can Predict the Survival of Patients With Lymphoma
-- Variations in biological variations in diffuse large B-cell lymphoma (DLBCL) influence whether a patient is likely to be cured by chemotherapy, according to a study published in the November 27 issue of the New England Journal of...
|
|
|
Cell Therapeutics Advances In Pre-Market On FDA Accepting Lymphoma Drug
Cell Therapeutics (CTIC: ) rose in pre-market trading, after the FDA accepted the company's Zevalin sBLA and granted it priority review.The stock was up 2 cents just after 8:20 am ET, climbing to 18 cents. If pre-market gains hold, the...
|
|
|
Allos cancer drug gets another orphan designation from FDA, protecting it from competition
WESTMINSTER, Colo.(AP) - Allos Therapeutics Inc. said Monday federal regulators have granted for the second time in a week a special status to the cancer drug pralatrexate that protects it from competition if approved. The...
|
